百利天恒：37.64亿元定增圆满收官

Core Viewpoint - Baili Tianheng successfully raised a total of 3.764 billion yuan through a private placement of A-shares, which will accelerate the development of its innovative drug pipeline and help the company enter the ranks of entry-level multinational corporations (MNCs) [1][4] Fundraising Details - The private placement attracted participation from 18 well-known domestic and international institutions, with a share price of 317 yuan, significantly above the base price of 266.02 yuan [1][2] - The issuance was highly anticipated in the market, with 30 investors submitting bids, and the final price set at 317 yuan per share, reflecting strong confidence in the company's R&D capabilities and growth prospects [1][4] Use of Proceeds - The raised funds will be fully allocated to innovative drug research and development projects, particularly focusing on the HIRE-ADC platform and GNC platform for innovative antibody drugs [2][3] - The ADC drug development platform will advance clinical trials for six ADC drugs, targeting over ten indications, including lung cancer and breast cancer [3] Clinical Development Plans - The company is conducting over 40 clinical trials for the BL-B01D1/iza-bren drug in China and the U.S., with several indications included in breakthrough therapy designations by the FDA and CDE [3] - The GNC platform will accelerate the clinical development of multi-specific antibodies, further enriching the company's innovative drug pipeline [3] Strategic Importance - This fundraising is a key initiative in the company's "Quality Improvement, Efficiency Enhancement, and Return to Action Plan" for 2025, with a significant increase in R&D investment [4] - The successful implementation of this private placement not only reflects market recognition of the value of innovative pharmaceutical companies but also marks the company's strategic commitment to becoming a global MNC under the guidance of the "Eight Policies" [4]